Skip Nav Destination
Issues
1 February 1994
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkBack Matter
- PDF Icon PDF LinkEditorial Board
ISSN 0008-5472
EISSN 1538-7445
Issue Sections
Journal Archive
Cancer Research (1941-Present; volumes 1-current)
(ISSN 0008-5472) Published twice monthly since 1987. From 1941-1986, published monthly.The American Journal of Cancer (1931-1940; volumes 15-40)
(ISSN 0099-7374) Published quarterly in 1931, bimonthly in 1932, and monthly from 1933 to 1940. The journal changed title to Cancer Research in 1941.The Journal of Cancer Research (1916-1930); volumes 1-14)
(ISSN 0099-7013) Published quarterly from 1916 through 1930 (publication was suspended from November 1922 to March 1924). The journal changed title to The American Journal of Cancer in 1931.Table of Contents
Articles
Loss of Heterozygosity on Chromosome 13 Is Common Only in the Biologically More Aggressive Subtypes of Ovarian Epithelial Tumors and Is Associated with Normal Retinoblastoma Gene Expression1
Timothy M. Kim; William F. Benedict; Hong-Ji Xu; Shi-Xue Hu; Jim Gosewehr; Mihaela Velicescu; Eric Yin; Jianping Zheng; Gerrit D'Ablaing; Louis Dubeau
Phase I and Pharmacokinetic Study of Ormaplatin (Tetraplatin, NSC 363812) Administered on a Day 1 and Day 8 Schedule
Russell J. Schilder; Frank P. LaCreta; Raymond P. Perez; Steven W. Johnson; James M. Brennan; Andre Rogatko; Sherri Nash; Ceclia McAleer; Thomas C. Hamilton; David Roby; Robert C. Young; Robert F. Ozols; Peter J. O'Dwyer
Two Molecular Pathways to Transitional Cell Carcinoma of the Bladder1
Charles H. Spruck, III; Petra F. Ohneseit; Mirella Gonzalez-Zulueta; David Esrig; Noriomi Miyao; Yvonne C. Tsai; Seth P. Lerner; Christoph Schmütte; Allen S. Yang; Richard Cote; Louis Dubeau; Peter W. Nichols; Gregers G. Hermann; Kenneth Steven; Thomas Horn; Donald G. Skinner; Peter A. Jones
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.